Your browser is no longer supported. Please, upgrade your browser.
Ayala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.82 Insider Own54.21% Shs Outstand14.42M Perf Week-2.95%
Market Cap126.63M Forward P/E- EPS next Y-2.77 Insider Trans0.00% Shs Float6.06M Perf Month-20.55%
Income-37.20M PEG- EPS next Q-0.80 Inst Own15.50% Short Float2.05% Perf Quarter-16.67%
Sales3.40M P/S37.25 EPS this Y-74.10% Inst Trans- Short Ratio3.62 Perf Half Y-9.05%
Book/sh2.97 P/B3.22 EPS next Y8.70% ROA-72.00% Target Price- Perf Year-27.38%
Cash/sh3.35 P/C2.85 EPS next 5Y- ROE-82.30% 52W Range7.74 - 28.68 Perf YTD-13.18%
Dividend- P/FCF- EPS past 5Y- ROI-78.70% 52W High-66.70% Beta-
Dividend %- Quick Ratio9.00 Sales past 5Y- Gross Margin0.00% 52W Low23.42% ATR0.93
Employees34 Current Ratio9.00 Sales Q/Q-20.00% Oper. Margin- RSI (14)30.88 Volatility8.90% 7.92%
OptionableNo Debt/Eq0.00 EPS Q/Q-1.00% Profit Margin- Rel Volume0.08 Prev Close10.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume34.31K Price9.55
Recom1.80 SMA20-11.76% SMA50-20.81% SMA200-20.83% Volume2,689 Change-4.50%
Jul-13-21Initiated Ladenburg Thalmann Buy $29
Dec-07-20Initiated ROTH Capital Buy $20
Jun-10-20Initiated Raymond James Outperform $24
Jun-02-20Initiated Oppenheimer Outperform $23
Jun-02-20Initiated Jefferies Hold $16
Jun-02-20Initiated Citigroup Buy $25
Sep-28-21 10:11AM  
Sep-27-21 06:32AM  
Sep-23-21 08:30AM  
Sep-17-21 05:28AM  
Sep-16-21 03:44PM  
Sep-02-21 08:00AM  
Sep-01-21 08:00AM  
Aug-13-21 09:15AM  
Aug-05-21 03:00PM  
Jul-29-21 01:47AM  
Jul-13-21 10:15AM  
Jul-07-21 04:29PM  
Jul-06-21 09:00AM  
Jun-18-21 11:55AM  
May-27-21 09:01AM  
May-14-21 09:35AM  
Apr-21-21 08:00AM  
Mar-25-21 08:00AM  
Mar-02-21 08:00AM  
Feb-22-21 08:55AM  
Feb-19-21 10:50AM  
Feb-18-21 11:52PM  
Jan-28-21 09:15AM  
Jan-20-21 08:33AM  
Jan-13-21 04:01PM  
Jan-05-21 08:00AM  
Jan-04-21 08:00AM  
Nov-26-20 08:15PM  
Nov-17-20 08:01AM  
Nov-05-20 08:00AM  
Sep-18-20 07:00AM  
Sep-15-20 12:14PM  
Sep-14-20 08:01AM  
Sep-08-20 08:01AM  
Aug-20-20 08:01AM  
Aug-13-20 08:01AM  
Aug-10-20 09:22AM  
Jul-27-20 08:01AM  
Jun-22-20 08:00AM  
Jun-10-20 11:30AM  
Jun-01-20 08:01AM  
May-12-20 04:01PM  
May-07-20 06:58PM  
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gordon Gary B.Chief Medical OfficerFeb 24Option Exercise5.163,00015,48011,520Feb 26 05:47 PM
Gordon Gary B.Chief Medical OfficerFeb 24Sale17.463,00052,3858,520Feb 26 05:47 PM
Mamluk RoniPresident & CEOFeb 24Sale17.4010,800187,919145,345Feb 24 05:42 PM
Mamluk RoniPresident & CEOFeb 23Sale17.897,126127,483156,145Feb 24 05:42 PM
Mamluk RoniPresident & CEOFeb 22Sale19.8615,200301,813163,271Feb 24 05:42 PM
Mamluk RoniPresident & CEOJan 21Sale15.041,40621,147178,471Jan 22 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20Option Exercise5.163,00015,48011,520Jan 22 04:05 PM
Mamluk RoniPresident & CEOJan 20Sale15.0319,466292,533179,877Jan 22 04:05 PM
Gordon Gary B.Chief Medical OfficerJan 20Sale15.033,00045,0848,520Jan 22 04:05 PM
SIDRANSKY DAVIDDirectorDec 23Buy11.56446250Mar 08 04:15 PM